|
|
Blood, 15 January 2004, Vol. 103, No. 2, pp. 679-688.
Prepublished online as a Blood First Edition Paper on September 22, 2003; DOI 10.1182/blood-2003-02-0540.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway
Catherine Kern,
Jean-François Cornuel,
Christian Billard,
Ruoping Tang,
Danielle Rouillard,
Virginie Stenou,
Thierry Defrance,
Florence Ajchenbaum-Cymbalista,
Pierre-Yves Simonin,
Sophie Feldblum, and
Jean-Pierre Kolb
From the U365 Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, Paris, France; Neurolab, Paris, France; EA1529/EMI9912, Service d'Hématologie, Paris, France; Service de Cytométrie, Institut Curie, Paris, France; and U404 INSERM, Lyon, France.
Tumor necrosis factor (TNF) superfamily members BAFF, or B-cell activation factor of the TNF family, and APRIL, a proliferation-inducing ligand, are involved in normal B-cell survival and differentiation. They interact with 3 receptors: BAFF-R, specific to BAFF; and TACI and BCMA, which are shared by BAFF and APRIL. We tested the potential role of these proteins in B-cell chronic lymphocytic leukemia (B-CLL) resistance to apoptosis. TACI and BAFF-R mRNAs were found in leukemic B cells. BAFF and APRIL mRNAs and proteins were detected in B-CLL leukemic cells and normal blood or tonsil-derived B lymphocytes. Yet, in contrast to normal B lymphocytes, BAFF and APRIL were expressed at the membranes of leukemic cells. Adding soluble BAFF or APRIL protected B-CLL cells against spontaneous and drug-induced apoptosis and stimulated NF- B activation. Conversely, adding soluble BCMA-Fc or anti-BAFF and anti-APRIL antibodies enhanced B-CLL apoptosis. Moreover, a soluble form of BAFF was detected using surface-enhanced laser desorption/ionization–time-of-flight mass spectrometry (SELDI-TOF MS) in the sera of B-CLL patients but not of healthy donors. Taken together, our results indicate that B-CLL cells can be rescued from apoptosis through an autocrine process involving BAFF, APRIL, and their receptors. Inhibiting BAFF and APRIL pathways may be of therapeutic value for B-CLL treatment.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S.-H. Kuo, P.-Y. Yeh, L.-T. Chen, M.-S. Wu, C.-W. Lin, K.-H. Yeh, Y.-S. Tzeng, J.-Y. Chen, P.-N. Hsu, J.-T. Lin, et al.
Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma
Blood,
October 1, 2008;
112(7):
2927 - 2934.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hewamana, S. Alghazal, T. T. Lin, M. Clement, C. Jenkins, M. L. Guzman, C. T. Jordan, S. Neelakantan, P. A. Crooks, A. K. Burnett, et al.
The NF-{kappa}B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target
Blood,
May 1, 2008;
111(9):
4681 - 4689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Tee, J.-L. Vigne, J. Yu, and R. N. Taylor
Natural and recombinant human glycodelin activate a proapoptotic gene cascade in monocyte cells
J. Leukoc. Biol.,
April 1, 2008;
83(4):
843 - 852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-W. Kim, D. W. Oleksyn, R. M. Rossi, C. T. Jordan, I. Sanz, L. Chen, and J. Zhao
Protein kinase C-associated kinase is required for NF-{kappa}B signaling and survival in diffuse large B-cell lymphoma cells
Blood,
February 1, 2008;
111(3):
1644 - 1653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. de Totero, R. Meazza, M. Capaia, M. Fabbi, B. Azzarone, E. Balleari, M. Gobbi, G. Cutrona, M. Ferrarini, and S. Ferrini
The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways
Blood,
January 15, 2008;
111(2):
517 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-T. Tai, X.-F. Li, I. Breitkreutz, W. Song, P. Neri, L. Catley, K. Podar, T. Hideshima, D. Chauhan, N. Raje, et al.
Role of B-Cell-Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.
Cancer Res.,
July 1, 2006;
66(13):
6675 - 6682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Fu, Y.-C. Lin-Lee, L. V. Pham, A. Tamayo, L. Yoshimura, and R. J. Ford
Constitutive NF-{kappa}B and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas
Blood,
June 1, 2006;
107(11):
4540 - 4548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. Brickner, A. M. Evans, J. K. Mito, S. M. Xuereb, X. Feng, T. Nishida, L. Fairfull, R. E. Ferrell, K. A. Foon, D. F. Hunt, et al.
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL
Blood,
May 1, 2006;
107(9):
3779 - 3786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Bischof, S. F. Elsawa, G. Mantchev, J. Yoon, G. E. Michels, A. Nilson, S. L. Sutor, J. L. Platt, S. M. Ansell, G. von Bulow, et al.
Selective activation of TACI by syndecan-2
Blood,
April 15, 2006;
107(8):
3235 - 3242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Elsawa, A. J. Novak, D. M. Grote, S. C. Ziesmer, T. E. Witzig, R. A. Kyle, S. R. Dillon, B. Harder, J. A. Gross, and S. M. Ansell
B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia
Blood,
April 1, 2006;
107(7):
2882 - 2888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yang, H. Hase, D. Legarda-Addison, L. Varughese, B. Seed, and A. T. Ting
B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells
J. Immunol.,
September 1, 2005;
175(5):
2814 - 2824.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shaughnessy Jr
APRIL showers cause CLL and myeloma to flower
Blood,
August 1, 2005;
106(3):
766 - 767.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ingold, A. Zumsteg, A. Tardivel, B. Huard, Q.-G. Steiner, T. G. Cachero, F. Qiang, L. Gorelik, S. L. Kalled, H. Acha-Orbea, et al.
Identification of proteoglycans as the APRIL-specific binding partners
J. Exp. Med.,
April 25, 2005;
(2005)
jem.20042309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Ogden, J. D. Pound, B. K. Batth, S. Owens, I. Johannessen, K. Wood, and C. D. Gregory
Enhanced Apoptotic Cell Clearance Capacity and B Cell Survival Factor Production by IL-10-Activated Macrophages: Implications for Burkitt's Lymphoma
J. Immunol.,
March 1, 2005;
174(5):
3015 - 3023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rodriguez, N. Martinez, F. I. Camacho, E. Ruiz-Ballesteros, P. Algara, J.-F. Garcia, J. Menarguez, T. Alvaro, M. F. Fresno, F. Solano, et al.
Variability in the Degree of Expression of Phosphorylated I{kappa}B{alpha} in Chronic Lymphocytic Leukemia Cases With Nodal Involvement
Clin. Cancer Res.,
October 15, 2004;
10(20):
6796 - 6806.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Novak, D. M. Grote, M. Stenson, S. C. Ziesmer, T. E. Witzig, T. M. Habermann, B. Harder, K. M. Ristow, R. J. Bram, D. F. Jelinek, et al.
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome
Blood,
October 15, 2004;
104(8):
2247 - 2253.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
